Century Therapeutics Inc stock is traded at $1.72, with a volume of 74,861. It is up +2.08% in the last 24 hours and up +16.67% over the past month. Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.
Previous Close:
$1.68
Open:
$1.74
24h Volume:
74,861
Relative Volume:
0.07
Market Cap:
$310.54M
Revenue:
$109.16M
Net Income/Loss:
-$107.78M
P/E Ratio:
-
EPS:
-$1.11
Net Cash Flow:
-$95.45M
1W Performance:
+2.69%
1M Performance:
+16.67%
6M Performance:
-25.11%
1Y Performance:
+204.46%
1-Day Range:
$1.64$1.74
1-Week Range:
$1.48$1.90
52-Week Range:
$0.435$3.04
Century Therapeutics Inc Stock (IPSC) Company Profile
Name
Century Therapeutics IncSector
HealthcareIndustry
BiotechnologyPhone
215-981-4000Address
25 N 38TH STREET, 11TH FLOOR, PHILADELPHIA, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS